Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (£272m) spanning five years over the United States' demand for confidential information.
The decision became public following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson has since explained that the United States was seeking biological samples for scientific study and commercial purposes while was not willing to share the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued dialogue to find a agreement acceptable to both sides so the country's critical HIV treatment initiative can proceed.
Broader Background
Zimbabwe's decision follows a similar case in Kenya, where a court suspended a related deal with the US after concerns were filed about the security of Kenyans' health data.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking government-to-government deals to boost transparency and responsibility.
Based on reports, Sixteen African countries have to date signed these new health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would provide the raw materials for medical research with no assurance that the final treatments would be available to our people should a future pandemic emerge."
Sovereignty and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining systems previously established through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This system is intended to guarantee that when a nation contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome ongoing dialogue with our American counterparts on how subsequent co-operation might be designed in a way that respects the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body expressed it understood the government's concerns, but suggested that negotiations need to persist since a large portion of the nation's Aids initiatives relied on foreign aid.
"Where technical issues arise, including those relating to data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," it added.
The situation underscores the continuing debate between accepting vital foreign assistance and safeguarding a country's data in an ever more data-driven world.